MYOV News and Press, Myovant Sciences Ltd. From 11/02/20

BASEL, Switzerland, Nov. 02, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced it will host a webcast and conference call to discuss corporate updates and financial results for its second fisca...

S even oral and poster presentations presented at the American Society for Reproductive Medicine (ASRM) 2020 Virtual Congress Oral presentation on efficacy and safety data from Phase 3 SPIRIT program sel ec ted as t he best clinical abstract in en...

Myovant's relugolix has 2 PDUFAs in the next 8 months. However, relugolix has strong competition from AbbVie and other companies. This and other factors make it an avoid. For further details see: Myovant: Relugolix Has Strong Competition

BASEL, Switzerland, Oct. 14, 2020 (GLOBE NEWSWIRE) -- Myovant Sciences (NYSE: MYOV), a healthcare company focused on redefining care for women and for men, today announced the appointment of Ryan Crowe as vice president, investor relations. In addition to managing day-to-day interactions wi...

Myovant Sciences' (MYOV) post-COVID-selloff rally came to an abrupt end on Tuesday, September 29, after it announced results on another secondary endpoint from the Phase 3 HERO clinical trial evaluating relugolix in men with advanced androgen-sensitive prostate cancer.Investors reacted s...

Gainers: Houston American Energy (HUSA) +245%.U.S. Energy (USEG) +167%.Greenpro Capital (GRNQ) +39%.Adial Pharmaceuticals (ADIL) +34%.Innodata (INOD) +33%.Digimarc (DMRC) +30%.VOC Energy Trust (VOC) +26%.New Concept Energy (GBR) +26%.Cardiff Oncology (CRDF) +22%.Novus Capital (...

Gainers: Adial Pharmaceuticals (ADIL) +33%, Spero Therapeutics (SPRO) +16%, LogicBio Therapeutics (LOGC) +14%, AngioDynamics (ANGO) +14%, Windtree Therapeutics (WINT) +10%.Losers: Myovant Sciences (MYOV) -21%, TransMedics Group (TMDX...

Myovant Sciences (MYOV) drops 20% premarket on robust volume in reaction to outcome of an additional secondary endpoint in the Phase 3 HERO study evaluating relugolix in men with advanced prostate cancer.Relugolix failed to demonstrate superiority compared to leuprolide acetate as m...

Rel u golix had a similar rate of castration resistance-free survival in the sub group of men with metastatic disease compared to leuprolide acetate (74% vs. 75%, respectively) and did not achieve statistical su...

P rostate cancer and uterine fibroids disproportionately impact Black Americans; racial disparities are exacerbated by inequities in healthcare access and COVID-19 pandemic Myovant expands ongoing efforts to advance health equity with gran...